🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

7+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 7 of 7 recruiting trials for “primary-membranous-glomerulonephritis”

RecruitingNCT07156149 ↗

Fabhalta Capsules Specified Drug-use Survey

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 23 sites📅 Started Sep 2025View details ↗
Phase 1RecruitingNCT07483827 ↗

A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

👨‍⚕️ Bernd Jilma, Prof., Medical University of Vienna📍 16 sites📅 Started Jun 2025View details ↗
RecruitingNCT07029542 ↗

Home Reported Outcomes in C3G Study

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 1 site📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT06209736 ↗

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

👨‍⚕️ Steve Whitaker, MD, Omeros Corporation📍 6 sites📅 Started Mar 2024View details ↗
Phase 3RecruitingNCT04817618 ↗

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 87 sites📅 Started Jul 2021View details ↗
Phase 2RecruitingNCT04183101 ↗

Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

👨‍⚕️ Diana Karpman, Region Skåne📍 4 sites📅 Started Oct 2020View details ↗
Phase 3RecruitingNCT03955445 ↗

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

👨‍⚕️ Novartis Pharmaceuticals, Novartis Pharmaceuticals📍 49 sites📅 Started Oct 2019View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →